Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers - Pharmaceutical Technology

This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines. This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines. Gilead and Vir will now collaborate to develop three next-generation TCEs for solid tumour indications. Credit: Sundry Photography / Shutterstock.com. Gilead Sciences and Vir Biotechnology have deepened their ties by inking a second deal, which will see the pair join forces to discover and engineer novel T-cell engager (TCE) therapies for solid tumours. Through this…

Source: Pharmaceutical Technology